Re: Farmas USA
MACK
The FDA grants Fast Track status to Merrimack Pharmaceuticals' (MACK +2.8%) MM-398 (nanoliposomal irinotecan injection) for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been treated previously with gemcitabine-based therapy.
Fast Track status provides for more frequent interactions with the FDA and a rolling review of the NDA in order to expedite the process.
«Después de nada, o después de todo/ supe que todo no era más que nada.»